Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...

Results of progression-free survival (PFS) and updated interim overall survival (OS) analyses from the phase 3 BREAKWATER study show that the combination of dual-targeted therapies encorafenib and ...

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...